US medical devices industry saw a rise of 7.14% in overall deal activity during March 2021, when compared with the last 12-month average, led by Hellman & Friedman’s $1bn private equity deal with Cardinal Health, according to GlobalData’s deals database.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 90 deals worth $4.63bn were announced in March 2021, compared with the 12-month average of 84 deals.
venture financing was the leading category in the month in terms of volume with 60 deals, which accounted for 66.7% of all deals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn second place was M&A with 23 deals, followed by private equity with seven transactions, respectively accounting for 25.6% and 7.8% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $2.23bn, while venture financing and private equity deals totalled $1.22bn and $1.18bn respectively.
US medical devices industry deals in March 2021: Top deals
The top five medical devices industry deals accounted for 58.9% of the overall value during March 2021.
The combined value of the top five medical devices deals stood at $2.73bn, against the overall value of $4.63bn recorded for the month.
The top five medical devices industry deals of March 2021 tracked by GlobalData were:
1) Hellman & Friedman’s $1bn private equity deal with Cardinal Health
2) The $695m acquisition of Resolution Bioscience by Agilent Technologies
3) Agiliti’s $475m acquisition of Northfield Medical
4) The $320m acquisition deal with Asuragen by Bio Techne
5) Organon &’s acquisition of Alydia Health for $240m.
